vimarsana.com

Page 269 - நோய் எதிர்ப்பு சக்தி டோவர்டீ நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NTU Singapore scientists develop oral insulin nanoparticles that could one day be an alternative to injections

Date Time Share NTU Singapore scientists develop oral insulin nanoparticles that could one day be an alternative to injections Scientists at Nanyang Technological University, Singapore (NTU Singapore) have developed insulin nanoparticles that may one day become the basis for an oral medicine, and an alternative to insulin injections for diabetic patients. In a pre-clinical study, the NTU Singapore team fed insulin-containing nanoparticles to rats and found that insulin increased in their blood minutes later. Insulin therapy is often an important part of treatment for diabetes, a metabolic disease that affects 422 million people globally . In Singapore, the number of diabetics is expected to grow to 1 million – almost a fifth of the population – in 2050 .

Tyee Poll: How Is the Pandemic Impacting Your Mental Health in the New Year?

Holding your breath may increase the chance of contracting Covid-19: Study

The IIT Madras study unravels mystery behind how particles are transported and deposited in the deep lung

COVID-19: Hospitals won t be able to handle serious cases soon — NCDC NEWS

Director General of the NCDC, Dr Chikwe Ihekweazu The Nigeria Centre for Disease Control says the country is now reaching a critical level, adding that the hospital capacity will no longer be able to cope with more serious COVID-19 cases. The Director-General of the NCDC, Dr Chikwe Ihekweazu, said this in a series of tweets on Monday while reacting to the spike in COVID-19 infections in the last one month. Ihekweazu said this as the fear of COVID-19 spread at the National Identity Management Commission grew on Monday because Nigerians besieged the NIMC offices following the workers’ suspension of the strike they embarked upon on Thursday.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.